Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery. Lysosomes are organelles (structures in cells) that contain digestive enzymes (substances that break down chemicals) that help keep the cells free of extra or worn out cell parts. Fluoxetine, a drug approved by the FDA to treat problems like depression and anxiety, can cause changes to structures in cells called lysosomes that then improve how well the chemotherapy drug temozolomide (TMZ) kills cancer cells in the brain.


Clinical Trial Description

The purpose of this study is to determine whether oral fluoxetine can induce lysosomal stress and enhance Temozolomide (TMZ)-induced cell death in patients diagnosed with recurrent malignant glioma. The primary objective is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery. Following consent, an optional biopsy may be performed to confirm recurrence of high-grade glioma. Recurrent glioma patients for whom retreatment with TMZ is appropriate and who are able to undergo tumor resection after 1 cycle of temozolomide will be enrolled in this study. Following enrollment, patients will randomly be assigned to (1:2) a study arm: control (n=10) or experimental (n=20). Within the experimental arm, two maintenance dose levels of fluoxetine are planned - 40mg OD (n=10) and 60mg OD (n=10). Patients randomized to the control arm will receive only 50 mg/m2 TMZ daily for 7 days (Days 6-12), followed by resection 21 days after initiation of the TMZ cycle. Patients randomized to the experimental arm will receive fluoxetine at 20 mg/day for 5 days (loading initiation dose) followed by a maintenance dose of 40 mg/day starting on Day 6 (dose level 1) or 60 mg/day starting on Day 6 (dose level 2) This truncated initiation period of fluoxetine has been discussed with the psychiatry department at Duke University Hospital and has been judged to be safe given the additional monitoring precautions that are being included as part of this study. On Day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12). Resection will occur 21 days after initiation of the TMZ cycle on Day 27. Patients will remain on their assigned dose of fluoxetine through resection and follow-up, as long as the treatment regimen is tolerated. The change between baseline and post-resection will be computed to determine if co-administration of fluoxetine and TMZ will result in increased expression of LAMP1 on resected glioma cells. Within each group, a Wilcoxon signed-rank test will be conducted to determine if there are significant within group changes. A Kruskal-Wallis test will compare the three patient groups (Control Group, Fluoxetine Group [low-dose], Fluoxetine Group [high-dose]) with respect to these changes. If data suggests that parametric method are appropriate, then analysis of variance and a paired t-test will be conducted. Risks commonly associated with fluoxetine include nausea, diarrhea, lack of appetite, dry mouth, upset stomach or heartburn, constipation, insomnia, anxiety, nervousness, drowsiness, tremor, unusual dreams, headaches, dizziness, yawning, swelling of face, low body temperature, sexual dysfunction, rash, hives and itching, sweating, flu-like symptoms, sore throat, stuffy nose, and fever. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05634707
Study type Interventional
Source Duke University
Contact Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Phone 919-684-5301
Email dukebrain1@dm.duke.edu
Status Recruiting
Phase Early Phase 1
Start date August 5, 2023
Completion date June 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05539677 - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Recruiting NCT04066465 - Neurocognitive Function After Proton Therapy in Children and Adolescents
Completed NCT02392078 - Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Not yet recruiting NCT02272452 - Assistance in Neurosurgery (ExtempoRMN) N/A
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Completed NCT02338037 - Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors Early Phase 1
Completed NCT05328739 - The Effect of Home Care Planned According to Orem in Patients With Primary Brain Tumor and Their Caregivers N/A
Completed NCT02034708 - Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Phase 4
Terminated NCT00629395 - Computerized Cognitive Training for Childhood Cancer Survivors N/A
Completed NCT04919993 - CBT for Insomnia in Primary Brain Tumor Patients N/A
Completed NCT04075370 - Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer
Completed NCT01242566 - Temozolomide in Elderly Patients With KPS < 70 Phase 2
Not yet recruiting NCT06439420 - CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Phase 2
Recruiting NCT01535430 - Assessment of Eloquent Function in Brain Tumor Patients
Completed NCT00285324 - Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis N/A
Recruiting NCT03684109 - Non-invasive Glioma Characterization Through Molecular Imaging N/A
Recruiting NCT05576103 - Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
Not yet recruiting NCT00265174 - Serum DNA Analysis: Potential Application for Diagnosis and Prognosis in Brain Cancer. N/A
Recruiting NCT05106296 - Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer Phase 1
Completed NCT04118426 - Cognitive Function After Radiation Therapy for Brain Tumours